Search

Your search keyword '"Esmagambetov, Ilias B"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Esmagambetov, Ilias B" Remove constraint Author: "Esmagambetov, Ilias B"
19 results on '"Esmagambetov, Ilias B"'

Search Results

1. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain

2. Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain

3. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

4. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

5. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

6. Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

7. rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19

8. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A

9. Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection

10. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A

11. Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection

13. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

14. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

16. Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection

17. Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant

18. An Open, Non-Randomised, 1/2 Phase Study on the Safety, Tolerability, and Immunogenicity of Single Dose 'Sputnik Light' Vaccine for Prevention of Coronavirus Infection in Healthy Adults

19. Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice.

Catalog

Books, media, physical & digital resources